273 related articles for article (PubMed ID: 29380929)
1. Checkpoint molecule expression by B and T cell lymphomas in dogs.
Hartley G; Elmslie R; Dow S; Guth A
Vet Comp Oncol; 2018 Sep; 16(3):352-360. PubMed ID: 29380929
[TBL] [Abstract][Full Text] [Related]
2. Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors.
Kumar SR; Kim DY; Henry CJ; Bryan JN; Robinson KL; Eaton AM
Vet Comp Oncol; 2017 Dec; 15(4):1527-1536. PubMed ID: 28111882
[TBL] [Abstract][Full Text] [Related]
3. Expression of Apoptosis-regulating Proteins Bcl-2 and Bax in Lymph Node Aspirates from Dogs with Lymphoma.
Meichner K; Fogle JE; English L; Suter SE
J Vet Intern Med; 2016 May; 30(3):819-26. PubMed ID: 27013187
[TBL] [Abstract][Full Text] [Related]
4. Immune regulation of canine tumour and macrophage PD-L1 expression.
Hartley G; Faulhaber E; Caldwell A; Coy J; Kurihara J; Guth A; Regan D; Dow S
Vet Comp Oncol; 2017 Jun; 15(2):534-549. PubMed ID: 26842912
[TBL] [Abstract][Full Text] [Related]
5. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
6. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
7. Affinity of the alpha4-beta1 integrin-targeting peptide LLP2A to canine lymphoma.
Zwingenberger AL; Kent MS; Shi C; Taylor SL; Chen X; Lam KS
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):298-304. PubMed ID: 22177114
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma.
Tagawa M; Kurashima C; Takagi S; Maekawa N; Konnai S; Shimbo G; Matsumoto K; Inokuma H; Kawamoto K; Miyahara K
PLoS One; 2018; 13(7):e0201222. PubMed ID: 30040869
[TBL] [Abstract][Full Text] [Related]
9. Use of fine needle aspirates and flow cytometry for the diagnosis, classification, and immunophenotyping of canine lymphomas.
Sözmen M; Tasca S; Carli E; De Lorenzi D; Furlanello T; Caldin M
J Vet Diagn Invest; 2005 Jul; 17(4):323-30. PubMed ID: 16130989
[TBL] [Abstract][Full Text] [Related]
10. PD-1 expression by canine T cells and functional effects of PD-1 blockade.
Coy J; Caldwell A; Chow L; Guth A; Dow S
Vet Comp Oncol; 2017 Dec; 15(4):1487-1502. PubMed ID: 28120417
[TBL] [Abstract][Full Text] [Related]
11. PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma.
Stevenson VB; Perry SN; Todd M; Huckle WR; LeRoith T
Vet Pathol; 2021 Jul; 58(4):692-698. PubMed ID: 34169800
[TBL] [Abstract][Full Text] [Related]
12. Study of DNA topoisomerase IIa expression in canine lymphomas and its potential role as a marker of sensitivity to anthracycline-based chemotherapy in dogs.
Klimiuk P; Lopuszynski W; Bulak K; Smiech A; Brzana A
Folia Histochem Cytobiol; 2020; 58(1):46-53. PubMed ID: 32176312
[TBL] [Abstract][Full Text] [Related]
13. Identification of altered MicroRNA expression in canine lymphoid cell lines and cases of B- and T-Cell lymphomas.
Uhl E; Krimer P; Schliekelman P; Tompkins SM; Suter S
Genes Chromosomes Cancer; 2011 Nov; 50(11):950-67. PubMed ID: 21910161
[TBL] [Abstract][Full Text] [Related]
14. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
16. Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry.
Gelain ME; Mazzilli M; Riondato F; Marconato L; Comazzi S
Vet Immunol Immunopathol; 2008 Feb; 121(3-4):179-88. PubMed ID: 17981339
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study of 82 cases of canine lymphoma in Austria based on the Working Formulation and immunophenotyping.
Guija de Arespacochaga A; Schwendenwein I; Weissenböck H
J Comp Pathol; 2007; 136(2-3):186-92. PubMed ID: 17416237
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
[TBL] [Abstract][Full Text] [Related]
20. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.
Fransen MF; Schoonderwoerd M; Knopf P; Camps MG; Hawinkels LJ; Kneilling M; van Hall T; Ossendorp F
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
